MedTrace Logo

Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa

NCT05040698 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-03-01

No results posted yet for this study

Summary

A 16 week exploratory, Proof of Concept study to evaluate the effect of Fostamatinib (12 weeks of treatment) upon cutaneous inflammation in Hidradenitis Suppurativa.

Conditions

Interventions

DRUG

Fostamatinib

Open label Fostamatinib

Sponsors & Collaborators

  • Rigel Pharmaceuticals

    collaborator INDUSTRY

  • Holdsworth House Medical Practice

    lead OTHER

Principal Investigators

  • John Frew, MBBS · Holdsworth House Medical Practice

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2023-01-13
Completion
2023-01-27
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05040698 on ClinicalTrials.gov